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Aim. We examined endocannabinoids (ECs) in relation to bariatric surgery and the association between plasma ECs and
markers of insulin resistance. Methods. A study of 20 participants undergoing bariatric surgery. Fasting and 2-hour plasma
glucose, lipids, insulin, and C-peptide were recorded preoperatively and 6 months postoperatively with plasma ECs (AEA, 2-AG)
and endocannabinoid-related lipids (PEA, OEA). Results. Gender-specific analysis showed differences in AEA, OEA, and PEA
preoperatively with reductions in AEA and PEA in females postoperatively. Preoperatively, AEAwas correlated with 2-hour glucose
(𝑟 = 0.55, 𝑃 = 0.01), HOMA-IR (𝑟 = 0.61, 𝑃 = 0.009), and HOMA %S (𝑟 = −0.71, 𝑃 = 0.002). OEA was correlated with weight
(𝑟 = 0.49, 𝑃 = 0.03), waist circumference (𝑟 = 0.52, 𝑃 = 0.02), fasting insulin (𝑟 = 0.49, 𝑃 = 0.04), and HOMA-IR (𝑟 = 0.48,
𝑃 = 0.05). PEA was correlated with fasting insulin (𝑟 = 0.49, 𝑃 = 0.04). 2-AG had a negative correlation with fasting glucose
(𝑟 = −0.59, 𝑃 = 0.04). Conclusion. Gender differences exist in circulating ECs in obese subjects. Females show changes in AEA
and PEA after bariatric surgery. Specific correlations exist between different ECs and markers of obesity and insulin and glucose
homeostasis.
1. Introduction
Recently, considerable interest has developed in the role that
the endocannabinoid system (ECS) plays in obesity, impaired
glucose homeostasis, and type 2 diabetes mellitus (T2DM)
[1]. The ECS comprises the endocannabinoids (ECs), the
enzymes involved in their synthesis and degradation, and
the cannabinoid (CB) receptors which are activated by ECs
[2]. ECs are bioactive lipid mediators that are synthesised
and released on demand [3]. The most comprehensively
studied ECs are the fatty acid amides, N-arachidonoyl
ethanolamine (AEA), N-palmitoylethanolamine (PEA), N-
oleoylethanolamine (OEA), and related N-acylethanolamine
(NAE) derivatives together with esters of arachidonic acid
including 2-arachidonoylglycerol (2-AG) [4–7]. The ECS is
critically important in the control and regulation of body
weight both centrally and peripherally. For example, activa-
tion of CB
1
by AEA and 2-AG is associated with increased
food intake, weight gain, and obesity, whilst OEA and PEA
are associated with the suppression of these effects. Debate
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exists on whether PEA and OEA can be considered as
endocannabinoid ligands as they have no activity at the classic
cannabinoid receptors (CB
1
and CB
2
) [8]. Increased levels
of ECs have been observed in the circulation and visceral
fat stores in obese subjects [9]; furthermore, adipocytes may
synthesise ECs de novo [10]. Obese humans have elevated
circulating levels of AEA and 2-AG compared to nonobese
controls of both genders [11–13]. A previous study has shown
higher circulating levels of 2-AG in insulin resistant obese
postmenopausal women [14] and in obese younger females
[15]. Overweight subjects with T2DM and hyperglycaemia
also have higher circulating ECs compared to age- and body
mass index- (BMI-) matched normoglycaemic subjects [10,
16].
Obesity is a major risk factor for insulin resistance and
T2DM. Activation of the peripheral ECS has been observed
in human obesity [11], resulting in adipogenesis, lipogenesis,
hepatic steatosis, and increased insulin resistance [17, 18].
AEA is metabolised by fatty acid amide hydrolase (FAAH).
Conflict exists within the literature with respect to FAAH
activity in obesity. Studies have described reduced expression
of FAAH in obese insulin resistant subjects [19]; other
studies have observed a positive correlation between FAAH
activity and BMI in a healthy population [20], but not in a
bariatric sample of subjects [2]. The former observation of
reduced FAAH in obese insulin resistant subjects together
with the observation that increased adiposity or BMI may
be associated with increased plasma ECs might result in
a further incremental increase in ECs [12, 13, 21]. Sipe et
al. demonstrated that circulating ECs predict obesity risk
and suggested targeting ECs as a novel strategy for treating
obesity [22]. Furthermore, CB
1
receptor blockade ameliorates
disturbances in glucose and insulin metabolism in mice fed a
high-fat diet [23]. CB
1
and CB
2
receptor antagonists such as
rimonabant have been studied within phase 3 clinical trials
[24].
Bariatric surgery is an effective treatment formorbid obe-
sity and is associated with reduced calorie intake, significant
weight loss, and resolution of T2DM [25]. Little information
is available on the effects of extreme weight loss, such as that
associated with bariatric surgery in relation to the ECS. Of
interest, a modest weight loss of 5% by diet or medication
(sibutramine) did not influence circulating EC levels in
postmenopausal women or obese subjects, respectively [11,
26], whereas a 10% weight reduction in abdominally obese
men was associated with a reduction in 2-AG levels [27].
Downregulation of AEA and 2-AG following Roux-en-Y
gastric bypass has been demonstrated in a rat model [28].
Furthermore, the effect of surgical gastric bypass-induced
weight loss on changes in ECs on coronary circulatory
dysfunction in morbidly obese individuals has been studied
[29]. The aim of our current study was to examine gender
differences in circulating ECs and changes in circulating
ECs in relation to bariatric surgery (as an extreme weight
loss intervention). ECs were measured preoperatively and
6 months postoperatively. We also studied the association
between circulating ECs and markers of obesity and insulin
and glucose homeostasis pre- and postoperatively.
2. Material and Methods
2.1. Study Participants. Approval for the study was obtained
from the Local Research Ethics Committee (South West
Wales; LREC reference 06/WMW02/7) and the Joint Scien-
tific Research Committee at Swansea University and ABM
University Health Board. Participants were identified and
recruited from patients undergoing a planned bariatric surgi-
cal procedure at theWelsh Institute of Metabolic and Obesity
Surgery (WIMOS) at Morriston Hospital, ABM University
Health Board, Swansea, Wales, UK. Informed consent was
obtained by trained personnel. Entry criteria at the outset
of the study included both sexes, age > 18 years, BMI >
40Kg/m2, and being physically fit for surgery. All subjects
had either previously diagnosed T2DM, impaired glucose
regulation, or T2DM diagnosed during an oral 75 g glucose
tolerance test (OGTT) at the start of the study. Partic-
ipants with impaired glucose regulation were those with
either impaired fasting glycaemia (IFG, 5.6–6.9mmol/L)
or impaired glucose tolerance (IGT, 2-hour glucose: 7.8–
11.0mmol/L) [30]. Participants with preexisting diabetes
treated with diet, oral agents, GLP-1 analogues, or insulin
were included. Participants with any acute concurrent illness
were excluded. At the time of recruitment no participant
volunteered a history of current or past cannabis use. We did
not measure plasma cannabinoid levels.
2.2. Study Design. Participants were recruited prospectively
from the bariatric surgical clinic and were not blindly
allocated to a surgical treatment option. As per local guid-
ance (within WIMOS) at the time, those with a BMI >
50Kg/m2 were routinely offered a biliopancreatic diversion
(BPD), whereas those with a BMI below this were offered
laparoscopic sleeve gastrectomy (LSG). LSG was performed
as a standard procedure, that is, sleeve fashioned around a
32F bougie taken from 5 cmproximal to the pylorus and up to
the left crus. BPD involved a distal gastrectomy (as described
by Scopinaro et al. [31]) and a 50 cm common channel.
All participants were recruited 1 month preoperatively and
followed up postoperatively at 6 months. Patients underwent
a standardised 75 g oral glucose tolerance test (OGTT)
(122mLs of Polycal 61.9 g/100mLof glucose, Nutricia Clinical
Care, Trowbridge, UK) pre- and postoperatively. There was
no standardised meal prescribed for the night before and
subjects were asked to fast from the midnight before the test
with diabetes related medication omitted.
2.3. Baseline Clinical and Biochemical Information. At the
time of the preoperative and postoperative OGTT the fol-
lowing clinical information was ascertained: age, gender,
past medical history, treatment, and duration of diabetes.
Baseline clinical measurements consisted of weight, height,
BMI, waist circumference, and systolic and diastolic blood
pressure. Baseline biochemical measurements (total choles-
terol, low density lipoprotein-cholesterol (LDL-C), high den-
sity lipoprotein-cholesterol (HDL-C), and triglycerides) were
performed within the local hospital accredited laboratory.
Fasting and 2-hour glucose, fasting lipids (Roche Modular
P800 Analyser), and fasting insulin and C-peptide (Roche
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E170 Modular Analyser) were also measured in the local
hospital laboratory. All samples were collected on ice, cen-
trifuged and separated within one hour of collection, and
subsequently stored at −80∘C until analysis.
2.4. Measurements of Insulin Sensitivity. The Homeosta-
sis Model Assessment (HOMA) was used to estimate
steady state beta cell function (%B) and insulin sensi-
tivity (%S) preoperatively and postoperatively. These were
calculated using the Oxford University online calculator
(http://www.dtu.ox.ac.uk/homacalculator/, accessed May 7,
2013) [32]. HOMA-IR is the reciprocal of HOMA%S.HOMA
%S represent values of 100% in normal young adults when
using currently available assays for insulin, specific insulin, or
C-peptide.The accuracy of thesemeasures has been validated
and has been shown to correlate with clamp-derived indices
of insulin sensitivity and secretion [33].The fasting C-peptide
to insulin ratio was calculated as an index of hepatic insulin
clearance [34].
2.5.Measurement of Plasma Endocannabinoid Levels. AnLC-
ESI+-MS/MS method was used for analysis of ECs in human
plasma samples based on a previously published method
[35]. Fasting plasma samples were obtained preoperatively
and postoperatively. Plasma was separated immediately and
stored at −80∘C immediately. Internal standards of 100 𝜇L of
2-AG-d8 (10 𝜇M) and 15 𝜇L of AEA-d8 (28𝜇M) were added
to aliquots of each plasma (0.4mL) sample or blank sample
(0.4mL water) or EC standards and vortexed briefly. Ethyl
acetate : hexane (9 : 1 v/v) was added to each sample, vortex-
mixed (10min), and centrifuged (13000 rpm, 10min, 4∘C).
The procedure was repeated and the supernatants pooled and
evaporated using a vacuum centrifugal evaporator. Prior to
analysis, each sample extract was reconstituted in 100𝜇L of
acetonitrile. The injection volume was 10 𝜇L. EC standards
(AEA, 2-AG, OEA, PEA, and internal standards 2-AG-d8,
AEA-d8) were purchased from Axxora Laboratory services,
Bingham, Nottingham, UK. The HPLC system used was
a Shimadzu SCL 10Avp (Shimadzu, Columbia, MD, USA)
coupled to a triple quadrupole ion-trap 4000 QTRAP mass-
spectrometer (ABI, UK) equipped with Turbo Spray ionisa-
tion interface. Analytes were separated chromatographically
on a Waters Symmetry C18 column (internal diameter 100 ×
2.1mm, particle size 3.5𝜇m) with a mobile phase flow rate of
0.3mL/minute. Multiple-reaction monitoring of individual
compounds using specific precursor and product mass-to-
charge (m/z) ratios allowed simultaneous measurement of
AEA, 2-AG, OEA, and PEA.
2.6. Statistical Methods. Statistical analysis was performed
using SPSS. Continuous variables that did not have a nor-
mal distribution (AEA, OEA, PEA, and 2-AG) underwent
log transformation to normalise the data for analysis and
are described with the geometric mean and approximate
standard deviation. For continuous variables, differences in
meanswere compared pre- andpostoperatively using a paired
sample 𝑡-test. Differences between males and females were
compared by ANOVA. We also examined the correlation
(Spearman’s correlation) between BMI, weight, waist cir-
cumference, fasting plasma glucose, 2-hour plasma glucose,
glycated haemoglobin (HbA
1c), systolic and diastolic blood
pressure, fasting insulin, and markers of insulin resistance
with plasma ECs pre- and postoperatively. In all cases a 𝑃 <
0.05 was considered statistically significant.
As our aim was to examine the effects of bariatric surgery
as an extreme weight loss intervention, we chose from
the outset to examine the surgical groups together rather
than separate. Our aim was therefore not to compare the
effects of LSG and BPD. This would have also reduced the
numbers to 10 within each group. As there are no previous
studies performed in this group of subjects, a baseline power
calculationwas not performed.We also chose from the outset
to examine for gender differences in circulating ECs.
3. Results
3.1. Participant Characteristics. Samples from twenty par-
ticipants were analysed. Of these, 10 underwent LSG and
10 underwent BPD. There were 10 females and 10 males
with a mean age of 49.8 ± 7 years. The baseline clinical
characteristics pre- and postoperatively are shown in Table 1.
3.2. Weight, Blood Pressure, Lipids, and Glucose Control Pre-
and Postoperatively. As shown in Table 1 and in line with
previous data, there was a significant mean weight reduction
of 35.4 kg at 6 months. This was associated with significant
reductions in waist circumference and BMI at 6 months.
No statistically significant changes were observed in systolic
and diastolic blood pressure, total cholesterol, LDL-C, and
triglyceride levels postoperatively.
3.3. Effects of Bariatric Surgery on Glucose and Markers of
Insulin Resistance. As shown in Table 1, significant changes
were observed in 2-hour plasma glucose and HbA
1c at 6
months. Following surgery, 20% of the subjects had T2DM
compared to 65% prior to surgery. There was a significant
reduction in the fasting insulin and an increase in hepatic
insulin clearance at 6months postoperatively.HOMA%Swas
significantly increased at 6 months. There was no significant
change in fasting C-peptide following surgery.
3.4. Effects of Bariatric Surgery on Circulating Plasma Endo-
cannabinoid Levels. In the sample as a whole, there were no
significant changes in circulating levels of AEA, OEA, PEA,
and 2-AG postoperatively (Table 1). We observed significant
differences in circulating levels of AEA, OEA, and PEA
betweenmales and females preoperatively (Table 2). Further-
more, in the females, significant reductions were observed
in postoperative circulating AEA and PEA compared to
preoperative circulating AEA and PEA (Table 2). Of interest,
the postoperative levels in the females were comparable to
the levels in the males pre- and postoperatively. No gender
differences in circulating ECs were observed postoperatively.
3.5. Temporal Correlations between BMI, Glycaemic Con-
trol, Insulin Resistance, and Endocannabinoids. As described
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Table 1: Pre- and postoperative clinical and biochemical measurements.
Measurement Preoperative (𝑛 = 20) Postoperative (𝑛 = 20) 𝑃
Weight (kg) 160.2 (44.2) 124.8 (29.4) <0.001
BMI (kg/m2) 57.3 (14.1) 45.4 (10.1) <0.001
Waist (cm) 143.7 (21.5) 123.4 (20.1) <0.001
Systolic BP (mmHg) 133 (18) 128 (16) 0.19
Diastolic BP (mmHg) 79 (9) 75 (10) 0.06
Cholesterol (mmol/L) 4.2 (0.9) 3.9 (1.1) 0.26
LDL-C (mmol/L) 2.2 (0.8) 2.1 (0.9) 0.73
HDL-C (mmol/L) 1.2 (0.3) 1.1 (0.3) 0.08
Triglyceride (mmol/L) 1.7 (0.9) 1.4 (0.4) 0.18
HbA1c (%) 7.2 (1.5) 6.1 (1.3) 0.02
HbA1c (mmol/L) 55 (43.1) 43 (37.3) 0.02
Fasting glucose (mmol/L) 7.8 (3.3) 6.0 (3.1) 0.13
2-hour glucose (mmol/L) 12.7 (4.9) 8.3 (5.9) 0.01
Fasting insulin (IU/mL) 27.9 (16.2) 11.4 (6.7) 0.002
Fasting C-peptide (ng/mL) 3.6 (1.5) 2.9 (1.5) 0.10
HOMA %S 305.8 (208.3) 617.5 (492.5) 0.03
HOMA- IR 0.4667 (0.3016) 0.3600 (0.4154) 0.32
C-pep: Insulin ratio 0.1744 (0.0996) 0.2741 (0.1246) 0.001
AEA (pmol/mL)∗ 0.21 (0.04) 0.19 (0.04) 0.33
OEA (pmol/mL)∗ 1.05 (0.13) 0.93 (0.18) 0.25
PEA (pmol/mL)∗ 0.83 (0.09) 0.74 (0.09) 0.10
2-AG (pmol/mL)∗ 5.0 (1.55) 4.2 (1.40) 0.14
∗Geometric mean and approximate standard deviation shown for log transformed data.
Table 2: Pre- and postoperative gender differences in ECs.
Measurement Preoperative Postoperative
Females Males 𝑃 Females Males 𝑃
AEA (pmol/mL)∗ 0.297 (0.042) 0.147 (0.021) <0.001 0.209 (0.049)† 0.165 (0.033) 0.30
OEA (pmol/mL)∗ 1.263 (0.125) 0.869 (0.085) 0.002 0.947 (0.232) 0.912 (0.127) 0.86
PEA (pmol/mL)∗ 0.964 (0.096) 0.720 (0.054) 0.005 0.759 (0.110)†† 0.713 (0.084) 0.67
2-AG (pmol/mL)∗ 5.163 (1.831) 4.019 (2.184) 0.43 5.156 (2.086) 3.249 (0.840) 0.51
∗Geometric and approx. SD shown. Log transformed.
†
𝑃 = 0.02, preoperative versus 6 months postoperatively.
††
𝑃 = 0.007, preoperative versus 6 months postoperatively.
within the methods, we chose from the outset to examine
the correlation between markers of obesity and insulin and
glucose homeostasis and ECs preoperatively and postoper-
atively. The results are shown in Table 3. For AEA, preop-
eratively, there were significant positive correlations with
2-hour plasma glucose (𝑟 = 0.55, 𝑃 = 0.01), HOMA-
IR (𝑟 = 0.61, 𝑃 = 0.009), and a negative correlation
with HOMA %S (𝑟 = −0.71, 𝑃 = 0.002); these were no
longer present postoperatively. Preoperatively, OEA had a
significant correlation with weight (𝑟 = 0.49, 𝑃 = 0.03), waist
circumference (𝑟 = 0.52, 𝑃 = 0.02), fasting insulin (𝑟 = 0.49,
𝑃 = 0.04), and HOMA-IR (𝑟 = 0.48, 𝑃 = 0.05). With respect
to PEA, preoperatively, there was a positive correlation with
fasting insulin (𝑟 = 0.49, 𝑃 = 0.04) and LDL-C (𝑟 = 0.44,
𝑃 = 0.04) and 2-AG had a negative correlation with fasting
plasma glucose (𝑟 = −0.59, 𝑃 = 0.04).
With respect to the circulating ECs, preoperatively, AEA
had significant correlationswithOEA and PEA (𝑟 = 0.52,𝑃 =
0.02 and 𝑟 = 0.71, 𝑃 < 0.001) and 6 months postoperatively
(𝑟 = 0.60, 𝑃 = 0.005 and 𝑟 = 0.61, 𝑃 = 0.005, resp.).
4. Discussion
In line with previous studies, we observed significant
improvements in T2DM following bariatric surgery [36–
38]. Using the American Diabetes Association criteria for
the diagnosis of diabetes based on plasma glucose, we
observed that 80% of participants had normal glucose levels
during the postoperative OGTT. Within the current study
group, we observed significant improvements postoperatively
in glycaemic control, insulin sensitivity (HOMA %S), and
hepatic insulin clearance.
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Table 3: Correlations between circulating ECs and markers of obesity and insulin and glucose homeostasis pre- and postoperatively.
Variable AEA OEA PEA 2-AG
BMI
0 months 0.17 (0.68) 0.42 (0.06) 0.30 (0.19) 0.07 (0.45)
6 months 0.24 (0.32) 0.17 (0.50) −0.21 (0.93) −0.16 (0.53)
Weight
0 months 0.10 (0.68) 0.49 (0.03) 0.36 (0.12) 0.20 (0.45)
6 months 0.01 (0.96) 0.01 (0.97) −0.23 (0.35) −0.16 (0.53)
Waist
0 months 0.10 (0.68) 0.52 (0.02) 0.40 (0.08) 0.26 (0.33)
6 months −0.13 (0.62) −0.04 (0.86) −0.28 (0.25) 0.11 (0.70)
Fasting glucose
0 months 0.15 (0.55) 0.05 (0.84) 0.09 (0.71) −0.59 (0.04)
6 months 0.54 (0.05) 0.11 (0.62) 0.18 (0.46) −0.09 (0.75)
2-hour glucose
0 months 0.55 (0.01) 0.11 (0.65) 0.17 (0.47) 0.003 (1.00)
6 months −0.02 (0.94) −0.24 (0.33) −0.13 (0.60) −0.42 (0.10)
HbA1c
0 months 0.44 (0.06) 0.22 (0.37) 0.20 (0.40) −0.12 (0.66)
6 months 0.09 (0.71) −0.13 (0.59) −0.00 (0.97) −0.35 (0.17)
Fasting insulin
1 month 0.28 (0.26) 0.49 (0.04) 0.49 (0.04) 0.18 (0.54)
6 months −0.03 (0.89) 0.06 (0.81) 0.08 (0.76) −0.19 (0.49)
HOMA S%
1 month −0.71 (0.002) −0.34 (0.18) −0.47 (0.06) 0.16 (0.57)
6 months −0.35 (0.16) −0.25 (0.33) −0.33 (0.18) −0.21 (0.44)
HOMA- IR
0 months 0.61 (0.009) 0.48 (0.05) 0.53 (0.03) 0.27 (0.32)
6 months 0.40 (0.1) 0.28 (0.27) 0.25 (0.31) 0.38 (0.15)
Systolic BP
0 months 0.40 (0.09) 0.11 (0.66) 0.25 (0.30) −0.01 (1.0)
6 month −0.13 (0.61) −0.27 (0.26) −0.06 (0.81) −0.07 (0.78)
Diastolic BP
0 months 0.48 (0.04) 0.01 (0.96) 0.14 (0.56) −0.52 (0.04)
6 months −0.06 (0.83) −0.08 (0.76) 0.08 (0.74) −0.23 (0.38)
LDL-C
0 months 0.15 (0.54) 0.15 (0.52) 0.44 (0.04) −0.02 (0.94)
6 months −0.27 (0.27) −0.26 (0.28) −0.04 (0.87) 0.13 (0.62)
HDL-C
0 months −0.21 (0.37) −0.12 (0.53) −0.31 (0.18) −0.73 (0.001)
6 months −0.32 (0.18) 0.18 (0.45) 0.28 (0.25) 0.03 (0.91)
2-AG
0 months 0.08 (0.76)
6 months −0.01 (0.98)
OEA
0 months 0.52 (0.02)
6 months 0.60 (0.005)
PEA
0 months 0.71 (<0.001)
6 months 0.61 (0.005)
The 𝑟 values are shown with the 𝑃 values in brackets. Significant correlations are shown in bold.
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Our aim was to examine changes in circulating ECs
in relation to bariatric surgery (as a weight loss interven-
tion), differences by gender, and the association between
plasma ECs and markers of insulin resistance before and
after bariatric surgery. In the whole group, prior to gender
stratification, we observed no changes in circulating AEA,
OEA, PEA, and 2-AG before and after bariatric surgery. This
is in line with previous studies where a modest weight loss
of 5% by diet or medication (sibutramine) did not influence
circulating ECs in postmenopausal women or obese subjects,
respectively [11, 26], but contradicts the effect of 10% weight
loss on 2-AG and AEA levels reported for obese men [27]
and an increase in PEA in postmenopausal women [14] with
a mean BMI of 32.9 Kg/m2. This may be due to the extremely
high BMI both pre- and postoperatively despite surgical
induced weight loss and may be unique to our study sample.
We observed significant gender differences preoperatively
which is in line with a previous study which described gender
differences in circulating levels of AEA, OEA, and PEA
[14]. Postoperatively, we observed significant reductions in
circulating AEA and PEA in females but not males. Of note,
there was no significant difference in weight, BMI, and waist
circumference between females and males preoperatively or
postoperatively. Furthermore, no significant differences were
observed between gender (females versus males) for changes
postoperatively in weight (38±18 versus 33±24 kg,𝑃 = 0.58),
BMI (14.0 ± 7.5 versus 9.6 ± 7.0 kg/m2, 𝑃 = 0.20), and waist
circumference (21.3 ± 6.8 versus 19.2 ± 6.8 cm, 𝑃 = 0.52).
No gender differences were seen for postoperative changes in
fasting glucose, 2-hour glucose, fasting insulin, HbA
1c, and
HOMA measurements. Therefore, the reason for this gender
difference is unclear but is likely to be related to an interaction
between sex hormones and the ECS. This is supported by
previous literature [39, 40] which supports a role for female
sex hormones in modulating EC activity. We would therefore
suggest that, for further studies examining circulating ECs,
gender stratification is essential. A limitation of our current
study was that we did not measure sex hormones nor did
we document menstrual history, but none of the female
participants had reported menopausal symptoms.
There is paucity in the published literature examining
the associations between circulating ECs and markers of
fat mass and glucose and insulin homeostasis. We observed
distinct associations between specific ECs and these markers.
Previous studies have shown that weight andwaist circumfer-
ence are accepted markers of insulin resistance [41] and that
circulating EC levels are associated with insulin resistance
[10, 16, 42]. Preoperatively, AEA had significant correlations
with 2-hour plasma glucose andmarkers of insulin resistance.
OEA was correlated with weight, waist circumference, and
insulin resistance. PEA had a positive correlation insulin
and 2-AG with fasting glucose. Therefore, the different ECs
appear to be associated with different markers of fat mass
and glucose and insulin homeostasis. However, AEA was
correlated with OEA and PEA. Therefore, there appear to
be complex and specific biochemical-clinical relationships.
These findings have not been described previously and
warrant further investigation. None of the above correlations
were observed postoperatively. One possible explanation for
this may be related to a change in diet following bariatric
surgery. A recent study has shown that obesity and high fat
dietary intake influences CB
1
receptor expression in skeletal
muscle and FAAH gene expression in subcutaneous adipose
tissue [43]. These effects were not observed in lean and
low fat diets. Another explanation is that genetic variation
within CB
1
receptor may influence metabolic function in
response to changes in diet or medication [44, 45]. Another
possible explanation may be related to changes in other
satiety hormoneswhich influence the ECS.Thesemay include
ghrelin and leptin, both of which are influenced by bariatric
surgery [46, 47] and other means of weight reduction [48].
This is an area which warrants further investigation.
Therapeutic interventions which target the ECS through
the blockade of CB
1
receptors have been extensively studied
and have shown benefits in glucose metabolism and insulin
resistance [21, 23, 49]. To the best of our knowledge, this
current study is the only one that has examined the rela-
tionship of ECs following extreme weight loss resulting from
bariatric surgery. Further work is required to explore these
findings to establish whether circulating ECs may have a
causal association with obesity and impaired glucose and
insulin homeostasis or whether they are merely a marker of
increased fat mass and associated metabolic dysregulation.
The gender differences relating to the ECs also require more
detailed examination.The current study adds to the available
literature examining the role of ECs in obesity and glucose
and insulin homeostasis. A limitation of our current study
is that this comprised a small number of 20 subjects. In
view of this number, we combined the two types of surgeries
which we acknowledge involve dissimilar mechanisms to
induce weight loss. The study was explorative in nature and
the data will add to the potential for a more robust larger
powered study within this interesting field of investigation.
Furthermore, future studies should examine the different
bariatric procedures in relation to circulating ECs.
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